Global pharmaceutical majors are restructuring clinical trial pipelines to capitalize on market demand for next-generation peptide-based therapies.
Clinical Expansion
Phase III trials are expanding beyond glycemic control into cardiovascular risk reduction, non-alcoholic steatohepatitis, and neurodegenerative conditions.
Manufacturing Constraints
Contract Development and Manufacturing Organizations are expanding specialized sterile fill-finish capacity to address widespread global supply shortfalls.